Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.

Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
Coverage includes:
• Novel therapeutic strategies
• High-throughput screening
• Therapeutic targets
• Combinatorial chemistry, parallel synthesis and library design
• Drug delivery
• ADME/Tox
• Advances in key compound classes and therapeutic areas
• Genomics and proteomics
• Automation and technology
• Virtual chemistry
• Informatics
• Business strategy
• Clinical trials
and other aspects of drug discovery.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Submission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at: http://www.drugdiscoverytoday.com/submit-a-paper/

Guest Editorial articles
Short Reviews
Keynote Reviews
Foundation Reviews
Features
Biotech focus articles

Editor
Stephen Carney
Advisory Editorial Board
Jürgen Bajorath
University of Bonn, Bonn, Germany
David Brayden
University College Dublin, Dublin, Ireland
Paul Caron
Vertex Pharmaceuticals Inc, Boston, Massachusetts, United States
David Cavalla
Numedicus Limited, Cambridge, United Kingdom
David Clark
Charles River Harlow, Harlow, United Kingdom
Dalia Cohen
Rosetta Genomics Inc, North Brunswick, New Jersey, United States
Donald Daley
Charles River Harlow, Harlow, United Kingdom
Sean Ekins
Hans-Peter Fischer
Genedata AG, Basel, Switzerland
Peter Ghazal
The University of Edinburgh, Edinburgh, United Kingdom
Christopher M. Hill
Merck Sharp and Dohme Ltd, Hoddesdon, United Kingdom
Nick Hird
Takeda Pharmaceutical Co Ltd, Osaka, Japan
Enoch Huang
Pfizer Global Research and Development Computational Sciences Center of Emphasis, Cambridge, Massachusetts, United States
Thomas Joos
Natural and Medical Sciences Institute at the University of Tubingen, Reutlingen, Germany
Vincent H.L. Lee
Chinese University of Hong Kong School of Pharmacy, New Territories, Hong Kong
David Lewin
YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, Connecticut, United States
Christopher A. Lipinski
Melior Discovery Inc, Exton, Pennsylvania, United States
Lorenz Mayr
Novartis Pharma AG, Basel, Switzerland
Nicholas Meanwell
Bristol-Myers Squibb Research, Wallingford, Connecticut, United States
Bilikallahalli Muralidhara
Acceleron Pharma, Cambridge, Massachusetts, United States
Mark Murcko
Disruptive Biomedical LLC, Holliston, Massachusetts, United States
Fajun Nan
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai, China
Pradeep Nathan
Syneos Health Inc Princeton, Princeton, New Jersey, United States
Gitte Neubauer
Cellzome AG, Heidelberg, Germany
Eric Neumann
Teranode Corp, Seattle, Washington, United States
Tim Peakman
UK Biobank, Stockport, United Kingdom
Norton Peet
Manuel Peitsch
Novartis Pharma AG, Basel, Switzerland
Kurt Rasmussen
USA
Janice Reichert
Tufts Center for the Study of Drug Development, Boston, Massachusetts, United States
John Reidhaar-Olson
Hoffmann-La Roche Inc, Little Falls, New Jersey, United States
Mike Romanos
GlaxoSmithKline Research and Development, Stevenage, United Kingdom
Ray Rowe
University of Bradford, Bradford, United Kingdom
Andreas Russ
University of Oxford, Oxford, United Kingdom
Esther Schmid
Pfizer Global Research and Development Sandwich, Sandwich, United Kingdom
Jonathan Sheldon
InforSense Ltd, London, United Kingdom
Michael Snyder
Stanford University, Stanford, California, United States
Susie Stephens
Eli Lilly and Company, Indianapolis, Indiana, United States
Robert Strausberg
J Craig Venter Institute, Rockville, Maryland, United States
Donny Strosberg
Scripps Research Institute Department of Infectology, Jupiter, Florida, United States
Yuichi Sugiyama
The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Sciences Molecular Pharmacokinetics, Tokyo, Japan
David Szymkowski
Xencor Inc, Monrovia, California, United States
Nick Terrett
MSD International GmbH, Kriens, Switzerland
Vladimir Torchilin, PhD, DSc
Northeastern University Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, Massachusetts, United States
Mark Whittaker
Evotec Oxford Asymmetry International UK Ltd, Milton, Abingdon, United Kingdom
Hans Winkler
Janssen Research and Development Beerse, Beerse, Belgium
Limsoon Wong
National University of Singapore, Singapore, Singapore
X.F. Steven Zheng
Rutgers Robert Wood Johnson Medical School Department of Pharmacology, Piscataway, New Jersey, United States